Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker RPRX
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 28, 2026 | Marshall Urist EVP, Research & Investments | RPRX Royalty Pharma plc | Sale | 4,126 | $57.88 | $238.8K Sale | Form 4 ↗ |
| Sep 22, 2026 | Christopher Hite EVP & Chairman, Partnering | RPRX Royalty Pharma plc | Sale | 3,927 | $58.93 | $231.4K Sale | Form 4 ↗ |
| Sep 22, 2026 | Christopher Hite EVP & Chairman, Partnering | RPRX Royalty Pharma plc | Sale | 96,073 | $58.51 | $5.6M Sale | Form 4 ↗ |
| Aug 18, 2026 | Christopher Hite EVP & Chairman, Partnering | RPRX Royalty Pharma plc | Sale | 100,000 | $59.97 | $6.0M Sale | Form 4 ↗ |
| Aug 13, 2026 | Terrance P. Coyne EVP & CFO | RPRX Royalty Pharma plc | Sale | 1,772 | $59.14 | $104.8K Sale | Form 4 ↗ |
| Aug 13, 2026 | Terrance P. Coyne EVP & CFO | RPRX Royalty Pharma plc | Sale | 9,230 | $58.59 | $540.8K Sale | Form 4 ↗ |
| Jul 1, 2026 | Marshall Urist EVP, Research & Investments | RPRX Royalty Pharma plc | Sale | 9,099 | $55.88 | $508.5K Sale | Form 4 ↗ |
| Jun 30, 2026 | Christopher Hite EVP & Chairman, Partnering | RPRX Royalty Pharma plc | Sale | 600 | $57.09 | $34.3K Sale | Form 4 ↗ |
| Jun 30, 2026 | Christopher Hite EVP & Chairman, Partnering | RPRX Royalty Pharma plc | Sale | 29,400 | $56.44 | $1.7M Sale | Form 4 ↗ |
| Jun 30, 2026 | Christopher Hite EVP & Chairman, Partnering | RPRX Royalty Pharma plc | Sale | 2,554 | $57.10 | $145.8K Sale | Form 4 ↗ |
| Jun 30, 2026 | Christopher Hite EVP & Chairman, Partnering | RPRX Royalty Pharma plc | Sale | 97,446 | $56.50 | $5.5M Sale | Form 4 ↗ |
| Jun 24, 2026 | Marshall Urist EVP, Research & Investments | RPRX Royalty Pharma plc | Sale | 9,098 | $55.18 | $502.0K Sale | Form 4 ↗ |
| Jun 23, 2026 | Christopher Hite EVP & Chairman, Partnering | RPRX Royalty Pharma plc | Sale | 117,592 | $54.47 | $6.4M Sale | Form 4 ↗ |
| Jun 23, 2026 | Christopher Hite EVP & Chairman, Partnering | RPRX Royalty Pharma plc | Sale | 32,408 | $54.11 | $1.8M Sale | Form 4 ↗ |
| May 26, 2026 | Terrance P. Coyne EVP & CFO | RPRX Royalty Pharma plc | Sale | 64,399 | $53.98 | $3.5M Sale | Form 4 ↗ |
| May 20, 2026 | Marshall Urist EVP, Research & Investments | RPRX Royalty Pharma plc | Sale | 13,684 | $52.75 | $721.8K Sale | Form 4 ↗ |
| May 14, 2026 | Marshall Urist EVP, Research & Investments | RPRX Royalty Pharma plc | Sale | 13,684 | $53.06 | $726.1K Sale | Form 4 ↗ |
| May 14, 2026 | Gregory Norden Director | RPRX Royalty Pharma plc | Sale | 3,045 | $53.00 | $161.4K Sale | Form 4 ↗ |
| Apr 28, 2026 | Terrance P. Coyne EVP & CFO | RPRX Royalty Pharma plc | Sale | 1,875 | $49.78 | $93.3K Sale | Form 4 ↗ |
| Apr 28, 2026 | Terrance P. Coyne EVP & CFO | RPRX Royalty Pharma plc | Sale | 32,916 | $49.78 | $1.6M Sale | Form 4 ↗ |
| Apr 1, 2026 | Terrance P. Coyne EVP & CFO | RPRX Royalty Pharma plc | Sale | 32,916 | $48.33 | $1.6M Sale | Form 4 ↗ |
| Apr 1, 2026 | Terrance P. Coyne EVP & CFO | RPRX Royalty Pharma plc | Sale | 1,875 | $48.33 | $90.6K Sale | Form 4 ↗ |
| Mar 23, 2026 | Terrance P. Coyne EVP & CFO | RPRX Royalty Pharma plc | Sale | 1,875 | $45.53 | $85.4K Sale | Form 4 ↗ |
| Mar 23, 2026 | Terrance P. Coyne EVP & CFO | RPRX Royalty Pharma plc | Sale | 32,916 | $45.53 | $1.5M Sale | Form 4 ↗ |
| Mar 2, 2026 | Terrance P. Coyne EVP & CFO | RPRX Royalty Pharma plc | Sale | 583 | $47.01 | $27.4K Sale | Form 4 ↗ |
| Mar 2, 2026 | Terrance P. Coyne EVP & CFO | RPRX Royalty Pharma plc | Sale | 1,292 | $46.67 | $60.3K Sale | Form 4 ↗ |
| Mar 2, 2026 | Terrance P. Coyne EVP & CFO | RPRX Royalty Pharma plc | Sale | 10,429 | $47.01 | $490.3K Sale | Form 4 ↗ |
| Mar 2, 2026 | Terrance P. Coyne EVP & CFO | RPRX Royalty Pharma plc | Sale | 22,487 | $46.67 | $1.0M Sale | Form 4 ↗ |
| Feb 23, 2026 | Terrance P. Coyne EVP & CFO | RPRX Royalty Pharma plc | Sale | 1,875 | $45.32 | $85.0K Sale | Form 4 ↗ |
| Feb 23, 2026 | Terrance P. Coyne EVP & CFO | RPRX Royalty Pharma plc | Sale | 32,916 | $45.32 | $1.5M Sale | Form 4 ↗ |
| Feb 4, 2026 | Terrance P. Coyne EVP & CFO | RPRX Royalty Pharma plc | Sale | 1,087 | $43.29 | $47.1K Sale | Form 4 ↗ |
| Feb 4, 2026 | Terrance P. Coyne EVP & CFO | RPRX Royalty Pharma plc | Sale | 19,076 | $43.29 | $825.8K Sale | Form 4 ↗ |
| Feb 3, 2026 | Terrance P. Coyne EVP & CFO | RPRX Royalty Pharma plc | Sale | 6,195 | $42.84 | $265.4K Sale | Form 4 ↗ |
| Feb 3, 2026 | Terrance P. Coyne EVP & CFO | RPRX Royalty Pharma plc | Sale | 108,759 | $42.84 | $4.7M Sale | Form 4 ↗ |
| Feb 2, 2026 | Terrance P. Coyne EVP & CFO | RPRX Royalty Pharma plc | Sale | 5,843 | $42.08 | $245.9K Sale | Form 4 ↗ |
| Feb 2, 2026 | Terrance P. Coyne EVP & CFO | RPRX Royalty Pharma plc | Sale | 102,581 | $42.08 | $4.3M Sale | Form 4 ↗ |
| Jan 30, 2026 | Marshall Urist EVP, Research & Investments | RPRX Royalty Pharma plc | Sale | 20,000 | $41.09 | $821.8K Sale | Form 4 ↗ |
| Jan 23, 2026 | Marshall Urist EVP, Research & Investments | RPRX Royalty Pharma plc | Sale | 20,000 | $40.26 | $805.2K Sale | Form 4 ↗ |
| Jan 20, 2026 | Terrance P. Coyne EVP & CFO | RPRX Royalty Pharma plc | Sale | 3,750 | $39.35 | $147.6K Sale | Form 4 ↗ |
| Jan 20, 2026 | Terrance P. Coyne EVP & CFO | RPRX Royalty Pharma plc | Sale | 65,832 | $39.35 | $2.6M Sale | Form 4 ↗ |
| Jan 16, 2026 | Marshall Urist EVP, Research & Investments | RPRX Royalty Pharma plc | Sale | 20,000 | $39.52 | $790.4K Sale | Form 4 ↗ |
| Jan 9, 2026 | Marshall Urist EVP, Research & Investments | RPRX Royalty Pharma plc | Sale | 20,000 | $40.78 | $815.6K Sale | Form 4 ↗ |
| Jan 2, 2026 | Marshall Urist EVP, Research & Investments | RPRX Royalty Pharma plc | Sale | 20,000 | $38.48 | $769.6K Sale | Form 4 ↗ |
| Jan 2, 2026 | Terrance P. Coyne EVP & CFO | RPRX Royalty Pharma plc | Sale | 3,750 | $38.42 | $144.1K Sale | Form 4 ↗ |
| Jan 2, 2026 | Terrance P. Coyne EVP & CFO | RPRX Royalty Pharma plc | Sale | 65,832 | $38.42 | $2.5M Sale | Form 4 ↗ |
| Dec 26, 2025 | Marshall Urist EVP, Research & Investments | RPRX Royalty Pharma plc | Sale | 20,000 | $39.32 | $786.4K Sale | Form 4 ↗ |
| Dec 19, 2025 | Marshall Urist EVP, Research & Investments | RPRX Royalty Pharma plc | Sale | 20,000 | $38.38 | $767.6K Sale | Form 4 ↗ |
| Dec 18, 2025 | George W. Lloyd EVP, Investments & CLO | RPRX Royalty Pharma plc | Sale | 30,654 | $38.50 | $1.2M Sale | Form 4 ↗ |
| Dec 17, 2025 | George W. Lloyd EVP, Investments & CLO | RPRX Royalty Pharma plc | Sale | 79,346 | $38.57 | $3.1M Sale | Form 4 ↗ |
| Dec 16, 2025 | Marshall Urist EVP, Research & Investments | RPRX Royalty Pharma plc | Sale | 20,000 | $38.32 | $766.4K Sale | Form 4 ↗ |
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 5:25 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances